Article

Stereotactic body radiation therapy for metastasis to the adrenal glands.

Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Expert Review of Anti-infective Therapy (Impact Factor: 2.28). 12/2012; 12(12):1613-20. DOI: 10.1586/era.12.125
Source: PubMed

ABSTRACT Many primary cancers can metastasize to the adrenal glands. Adrenalectomy via an open or laparoscopic approach is the current definitive treatment, but not all patients are eligible or wish to undergo surgery. There are only limited studies on the use of conventional radiation therapy for palliation of symptoms from adrenal metastasis. However, the advent of stereotactic body radiation therapy (SBRT) - also named stereotactic ablative radiotherapy for primary lung cancer, metastases to the lung, and metastases to the liver - have prompted some investigators to consider the use of SBRT for metastases to the adrenal glands. This review focuses on the emerging data on SBRT of metastasis to the adrenal glands, while also providing a brief discussion of the overall management of adrenal metastasis.

1 Follower
 · 
213 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Locally advanced non-small cell lung cancer is a disease typified by poor clinical outcomes. Patients treated with definitive radiation or chemoradiation have high rates of local tumor progression and distant metastasis. Tumor dose escalation using conventionally fractionated radiation is limited by toxicity to adjacent normal tissues. Novel treatment modalities such as stereotactic body radiation therapy or charged particle therapies potentially represent methods to dose escalate without increasing the risk of normal tissue toxicity. Here, we review the technologies of stereotactic body radiation therapy and charged particles, the reported clinical success with these modalities, and potential implementation into treatment regimens for locally advanced non-small cell lung cancer.
    The Cancer Journal 01/2013; 19(3):272-281. DOI:10.1097/PPO.0b013e31829452a5 · 3.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Stereotactic body radiotherapy (SBRT) has been used extensively in patients with lung, liver and spinal tumors, and the treatment outcomes are very favorable. For certain conditions such as medically inoperable stage I non-small-cell lung cancer, liver and lung oligometastases, primary liver cancer and spinal metastases, SBRT is regarded as one of the standard therapies. In the recent years, the use of SBRT has been extended to other disease conditions and sites such as recurrent head and neck cancer, renal cell carcinoma, prostate cancer, adrenal metastasis, pancreatic cancer, gynecological malignancies, spinal cord compression, breast cancer, and stage II-III non-small-cell lung cancer. Preliminary data in the literature show promising results but the follow-up intervals are short for most studies. This paper will provide an overview of these emerging applications.
    Future Oncology 05/2014; 10(7):1299-310. DOI:10.2217/fon.14.13 · 2.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review To discuss the emerging roles of stereotactic ablative radiotherapy (SABR) in patients with metastatic renal cell carcinoma (RCC). Recent findings RCC tumours are not as radio-resistant as previously thought, as local control rates of tumours treated with SABR are high. Therefore, SABR is an attractive treatment option for RCC tumours in which effective long-term palliation of symptoms or local control is desired. Like surgical resection of metastatic tumours, SABR can also be used as a method of eradicating oligometastases to potentially 'cure' or offer prolonged disease-free survival in patients with low-volume metastatic disease. In patients who develop progression of a solitary or few tumours (termed oligoprogression), SABR to the progressing 'rogue' tumours may delay the need to start or change systemic therapy. Finally, there is the potential for SABR to improve the efficacy of immunotherapy for metastatic RCC, given the known immune-modulated abscopal effect of radiotherapy. Summary SABR is increasingly being used in metastatic RCC patients, given the great potential to improve various outcomes. More prospective clinical trials are needed to identify and quantify the clinical benefits.
    Current Opinion in Supportive and Palliative Care 07/2014; 8(3). DOI:10.1097/SPC.0000000000000074